Talaris Raises $115M for Clinical Trials Testing FRC001 Cell Therapy for dcSSc
Talaris Therapeutics has raised $115 million in financing, which will be used to support the clinical development of its lead therapeutic candidate, FCR001, designed to promote immune tolerance and allow patients to stop taking immunosuppressive medications after a transplant. The newly raised funds…